U.S. Markets closed

Vivos Inc. (RDGL)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2500-0.0092 (-3.57%)
At close: 3:59PM EST

Vivos Inc.

719 Jadwin Avenue
Richland, WA 99352
United States
509 736 4000
http://www.radiogel.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees1

Key Executives

NameTitlePayExercisedYear Born
Dr. Michael K. KorenkoCEO, Pres & Director120kN/A1946
Dr. Carlton M. CadwellIndependent Chairman & Sec.N/AN/A1945
Mr. Michael H. Pollack CPA, CPAChief Financial OfficerN/AN/A1966
Dr. David J. Swanberg M.S., P.E.Chief Technical Mang.N/AN/A1957
Dr. Nigel R. StevensonChief Science OfficerN/AN/AN/A
Dr. Fu-Min SuChief Radio Chemist & Radiation Safety OfficerN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 is headquartered in Richland, Washington.

Corporate Governance

Vivos Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.